Over the past decade, the Healthcare IT sector has evolved into a set of distinct, data-driven markets with separate ecosystems of specialized platforms. From facility operations to clinical research, each solution now addresses a specific challenge within the healthcare system. Artificial Intelligence and Quantum Computing technologies have the potential to impact the pace and scale of the Healthcare IT evolution.
This evolution has also reshaped investor expectations around growth and profitability. Early-stage health-tech companies were often valued on vision and growth. Today, the market rewards execution, recurring revenue, and validated outcomes. As the HCIT space transitions from story-driven to metrics-driven, companies pursuing the public markets must demonstrate credible paths to profitability, defensible business models, and measurable impact to customers, physicians and patients.
Valuations in the Healthcare IT sector are driven by a company’s ability to capitalize on market opportunities in a sustained and profitable manner. Revenue growth, competitive differentiation, barrier to displacement, scale and development/commercial costs are key drivers of multiples in the public markets. Visibility/Predictability of revenue is often evaluated by the recurring vs transactional nature of the revenue stream, customer concentration, competition and long-term growth implications of the technology. Stating the obvious, highly predictable revenue and profit streams are coveted by investors and valued relatively based on investor confidence in the future.
Below, we outline the five key subsectors defining the next era of healthcare IT and the metrics that matter most to investors evaluating them.
1. Technology Enabling Better Facility or Practice Operations
This segment includes software that improves how healthcare facilities run day to day; billing, scheduling, collections, CRM, and revenue-cycle management. These systems have become the backbone of healthcare’s administrative infrastructure, where automation directly translates to better margins at facilities.
What Investors Watch:
Retention, low concentration, and consistent recurring revenue are critically important. Investors also look for quantifiable efficiency gains at customers; improved collections, faster claim resolution, and streamlined workflows that drive margin expansion. The strongest operators present credible visibility to EBITDA or free cash flow within two years of going public, supported by disciplined spending and customer scalability.
2. Technology Supporting Physician Decision-Making
Software in this category enhances how clinicians interpret information and deliver care within the clinical workflow. These include electronic medical records, decision support tools, and analytics platforms that translate large volumes of patient data into actionable guidance at the point of care. The focus has shifted from simply digitizing documentation to optimizing medical judgment and treatment alignment in real time.
What Investors Watch:
Numbers of users, utilization rates, contract terms/duration, and proof of improved clinical efficiency and patient care are important. Independent validation such as stronger adherence to clinical guidelines, reduced unnecessary utilization, or measurable time savings reinforces credibility. Scale and adoption by hospital systems, large physician practices, established care-delivery systems is important to the validation of the technology in the eyes of investors. Investors value companies that demonstrate their software tangibly improves care quality and operational throughput while embedding deeply into physician workflows.
3. Technology Powering Clinical Drug Development
Platforms supporting R&D, spanning modeling and simulation, proteomics & genomics, and clinical-trial enablement, sit at the intersection of software and life sciences. Software and tech capabilities that can enhance or accelerate drug discovery, development, patient selection/targeting, etc. can have exposure to drug development economics with royalties. As biopharma pipelines expand, these technologies have become indispensable to accelerating discovery and improving clinical trial execution.
What Investors Watch:
Contracted backlog, recurring SaaS or data-subscription revenue, and enterprise adoption across sponsors are important metrics. Long-term partnerships with CROs or biopharma validate stickiness and scale. Narratives around AI or machine learning resonate most when supported by measurable reductions in time or cost within the research and development process. Regulatory guidance and acceptance of new technology is a lynchpin to broad based adoption in drug development. The “dream” for these technologies is to reduce, not bend, the all-in cost curve of drug development with improvement in the clinical success rate of IND’s eventually becoming commercially available therapies.
4. Technology Advancing Diagnostics and Data-Driven Treatment
This segment encompasses imaging platforms, diagnostic visualization, connected sensors, and AI-driven analytics that generate and interpret new streams of patient data. Unlike workflow software, these solutions sit closer to the point of diagnosis, using advanced computation to detect, quantify, and predict disease earlier and more accurately.
What Investors Watch:
Validated accuracy with published data, and real world evidence, drives recurring revenue opportunity. Investors increasingly focus on gross margins as a key indicator of business mix durability; specifically, how much revenue is driven by higher-margin software and data services versus lower-margin hardware sales. Customer acquisition costs and opex requirements are scrutinized. The strongest companies show how AI and automation improve throughput, precision, and clinical utility, creating sustained value as data volumes and algorithmic performance compound over time. Here too, the goal is to refine the drug research and development process to identify patients who, biologically, are most likely to benefit from therapies.
5. Direct-to-Consumer (DTC) Enablement
DTC healthcare technology has evolved from simple engagement tools into integrated platforms that educate, inform, and empower patients to manage their health. Telehealth, digital therapeutics, and personalized care navigation solutions now anchoring this segment. The consumerism of healthcare is rapidly evolving mostly around “lifestyle” choices that can be managed with therapeutics; weight loss, hair loss, hormone therapies, longevity, mental health for example.
What Investors Watch:
Tangible market opportunity and strategy to penetrate, capture and retain consumer market/mind share. Cohort retention, customer acquisition cost payback within twelve months, and lifetime value exceeding three times acquisition cost. Sustainable models show improving unit economics over time and continued engagement beyond initial acquisition. The DTC names that will define the next wave of IPOs are those combining personalized experiences with verified outcomes and predictable subscription or reimbursement revenue.
Building Durable Value in a Segmented Market
Healthcare IT is no longer a single asset class. Each subsegment now carries its own set of economic models, proof points, and valuation frameworks mostly grounded in software fundamentals. Whether focused on enabling providers, empowering patients, or supporting research, success increasingly depends on disciplined communication to users and credible metrics for investors.
The management teams that align their investor messaging around identifiable growth drivers, high-quality recurring revenue, profitability timelines, validated outcomes, and consistent KPI definitions will be best positioned to earn long-term credibility in the public markets. Transparent communication and strategic clarity remain the foundation of durable value creation in Healthcare IT.
In Conclusion
For more insight into how Gilmartin partners with healthcare companies to refine positioning and prepare for the capital markets, please visit our Resources Section or contact our team to discuss how we can support your investor communications strategy.
Authored by: David Deuchler (Managing Director), Gilmartin Group & Nick Bouton (Analyst), Gilmartin Group